CDEK
← All drugs Report issue

polio, inactivated poliovirus vaccine

Trade name: Salk Vaccine

Vaccineapproved

Approved

Apr 2, 1955

Polio vaccines are vaccines used to prevent poliomyelitis (polio). Two types are used: an inactivated poliovirus given by injection (IPV) and a weakened poliovirus given by mouth (OPV). The World Health Organization (WHO) recommends all children be fully vaccinated against polio. The two vaccines have eliminated polio from most of the world, and reduced the number of cases reported each year from an estimated 350,000 in 1988 to 33 in 2018. — Wikipedia

Clinical trial activity

50 trials · 49 clinical orgs · 2 marketing orgs

Phase 1
6
Phase 2
25
Phase 3
15
Phase 4
16

Earliest trial started Nov 1, 2000 (NCT00729001)

Timeline

1950s

  1. Apr 2, 1955

    Earliest FDA Approval

2000s

  1. Jan 1, 2000

    GlaxoSmithKline — Earliest Phase 2 Sponsor(trial)

  2. Feb 4, 2000

    Sanofi-Aventis — First NDA Organization

  3. Feb 4, 2000

    Sanofi-Aventis — NDA Secondary Org

  4. Feb 4, 2000

    Sanofi-Aventis — NDA Organization

  5. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

  6. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  7. Jun 24, 2008

    GlaxoSmithKline — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Biological vaccine - induces immune response

  • PoliovirusOTHER

    Poliovirus other

  • PoliovirusImmunity, active

    Poliovirus immunity, active

Approval history

  • approvedApr 2, 1955

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bio-polio
  • imovax polio
  • inactivated poliomyelitis vaccine
  • inactivated polio vaccine
  • inactivated poliovirus vaccine
  • inactivated types 1, 2, and 3 poliovirus, d antigens
  • injectable inactivated types 1, 2 and 3 poliovirus vaccine
  • ipol
  • ipol
  • polio, inactivated poliovirus vaccine, higher potency
  • polio, inactivated poliovirus vaccine (salk)
  • poliomyelitis vaccine
  • poliorix
  • poliovirus vaccine inactivated
  • poliovirus vaccine inactivated (monkey kidney cell)
  • trivalen inactivated poliovirus vaccine
  • trivalent inactivated poliovirus vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06748612Phase 4Jan 28, 2025International Center for Diarrheal Disease Research
NCT05327426Phase 1Apr 1, 2022University of Vermont, World Health Organization
NCT05163561Phase 3Jan 10, 2022International Center for Diarrheal Disease Research, Serum Institute of India Pvt. Ltd.
NCT04027036Phase 2Oct 1, 2019Government of Mozambique, World Health Organization
NCT03723837Phase 4Nov 15, 2018Centers for Disease Control and Prevention (CDC), Tribhuvan University, World Health Organization
NCT03614533Phase 2Oct 15, 2018Bill and Melinda Gates Foundation, Groupe de Recherche Action en Santé (GRAS), Burkina Faso, University of Maryland
NCT03566940Phase 2Jul 31, 2018Janssen Pharmaceutica NV
NCT04220515Phase 4Feb 8, 2018Chinese Academy of Medical Sciences, Government of China
NCT03202719Phase 4Nov 5, 2017Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research
NCT03032588Phase 1Sep 14, 2017Janssen Pharmaceutica NV, Johnson and Johnson
NCT03526978Phase 3Aug 8, 2017Government of China, Sinovac Biotech Co., Ltd
NCT03286803Phase 4Aug 1, 2017Aga Khan University, World Health Organization
NCT03169725Phase 2/Phase 3 (Phase 3)May 31, 2017LG
NCT02775942Phase 2Nov 1, 2015Government of Vietnam
NCT03614702Phase 3Sep 15, 2015Chinese Academy of Medical Sciences, Government of China
NCT02347423Phase 2Feb 1, 2015Bill and Melinda Gates Foundation, IQVIA, Larix A/S, Statens Serum Institut
NCT02280447Phase 1/Phase 2 (Phase 2)Nov 1, 2014Bill and Melinda Gates Foundation, CCBR Clinical Research, Larix A/S, Statens Serum Institut
NCT01810731Phase 2/Phase 3 (Phase 3)Apr 1, 2014Centers for Disease Control and Prevention (CDC), Government of Kenya, Kenya Medical Research Institute
NCT02005536Phase 4Dec 1, 2013Sanofi
NCT01997632Phase 1Nov 1, 2013Ghent University
Showing 20 of 50 trials
Page 1 / 3

Organizations

Research & Development (49)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit101042000
Centers for Disease Control and Prevention (CDC)Government9432001
SanofiFor profit8832005
World Health OrganizationGovernment7042001
Government of ChinaGovernment6042008
Chinese Academy of Medical SciencesAcademic/Hospital5542008
Bill and Melinda Gates FoundationAcademic/Hospital4022013
International Center for Diarrheal Disease ResearchAcademic/Hospital4122012
Sanofi-AventisFor profit4022005
Aga Khan UniversityAcademic/Hospital3312012
All India Institute of Medical SciencesAcademic/Hospital2012009
Janssen Pharmaceutica NVFor profit2122017
Larix A/SFor profit2012014
NanoPass Technologies LtdFor profit2022012
PATHAcademic/Hospital2212009
Statens Serum InstitutAcademic/Hospital2212014
University of Alabama, BirminghamAcademic/Hospital2112009
CCBR Clinical ResearchFor profit1012014
Christian Medical College, Vellore, IndiaAcademic/Hospital1012012
Cuban Ministry of Public HealthAcademic/Hospital1012001
49 organizations
Page 1 / 3

Marketing (3)

OrganizationOrg typeRelationshipDate
GlaxoSmithKlineFor profitNDA2Jun 24, 2008
Sanofi-AventisFor profitNDA2Feb 4, 2000
Sanofi-AventisFor profitNDAFeb 4, 2000